Comparative Outcomes of Adrenalectomy, Mineralocorticoid Receptor Antagonist, and Percutaneous Adrenal Ablation for Primary Aldosteronism: A Systematic Review and Network Meta-Analysis
American Journal of Hypertension · 2025
DOI: 10.1093/ajh/hpaf029 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift American Journal of Hypertension, 2025. Verfasst von Liyuan Yuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hypertension and Endocrinology, Daping Hospital, Center for Hypertension and Metabolic Dieases, Army Medical University of PLA, Center …. Hauptthemen laut MEDLINE: Adrenalectomy, Catheter Ablation, Hyperaldosteronism, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND Percutaneous adrenal ablation (PAA) is an effective and safe therapy for treating patients with primary aldosteronism (PA). However, its effectiveness in comparison to that of adrenalectomy (ADX) and mineralocorticoid receptor antagonists (MRAs) remains unclear. METHODS Databases were searched including PubMed, Embase, and The Cochrane Library. Studies included patients with PA who received two of three different treatments (ADX, MRAs, or PAA) and reported our interested outcomes, including blood pressure, serum potassium, and the aldosterone-to-renin ratio (ARR). RESULTS In a total of 10,681 patients from 47 studies were identified. Both ADX and PAA showed superior clinical success (systolic blood pressure (BP): ADX: −4.69 (−6.4, −2.95), PAA: −3.96 (−9.05, 0.99); diastolic BP: ADX: −3.14 (−4.55, −1.85), PAA: −2.99 (−6.96, 0.98)) compared with MRAs. According to the Bayesian ranking curves (surface under the cumulative ranking values), ADX ranked first for all outcomes of interest (systolic BP: 81.02%, diastolic BP: 76.95%, serum potassium: 96.55%, and ARR: 88.03%), while PAA ranked second for all outcomes (systolic BP: 65.94%, diastolic BP: 69.66%, serum potassium: 50%, and ARR: 45.14%). CONCLUSIONS The findings of this network meta-analysis suggest that PAA could be an alternative treatment for patients with PA who are unable to opt for surgery or MRA therapy, and its clinical and biochemical success falls between those of ADX and MRAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hypertension and Endocrinology, Daping Hospital, Center for Hypertension and Metabolic Dieases, Army Medical University of PLA, Center for Hypertension and Metabolic Diseases, Chongqing Institute of Hypert…
- School of Mathematics and Statistics, Southwest University, Chongqing, China.
- Chongqing institute for Brain and Intelligence, Chongqing, China.
ORCID-Profile: Zhiming Zhu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yuan, L., Li, X., Sun, F., Tang, Y., Wang, W., Liu, W., Sun, X., Luo, Y., Bu, X., Lu, Z., Liu, D., Li, Q., & Zhu, Z. (2025). Comparative Outcomes of Adrenalectomy, Mineralocorticoid Receptor Antagonist, and Percutaneous Adrenal Ablation for Primary Aldosteronism: A Systematic Review and Network Meta-Analysis. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpaf029
Vancouver
Yuan L, Li X, Sun F, Tang Y, Wang W, Liu W, et al. Comparative Outcomes of Adrenalectomy, Mineralocorticoid Receptor Antagonist, and Percutaneous Adrenal Ablation for Primary Aldosteronism: A Systematic Review and Network Meta-Analysis. American Journal of Hypertension. 2025. doi:10.1093/ajh/hpaf029
BibTeX
@article{Yuan2025,
author = {Yuan, Liyuan and Li, Xinyi and Sun, Fang and Tang, Yi and Wang, Wuhao and Liu, Wei and Sun, Xiaona and Luo, Yushuang and Bu, Xiaona and Lu, Zongshi and Liu, Daoyan and Li, Qiang and Zhu, Zhiming},
title = {Comparative Outcomes of Adrenalectomy, Mineralocorticoid Receptor Antagonist, and Percutaneous Adrenal Ablation for Primary Aldosteronism: A Systematic Review and Network Meta-Analysis},
journal = {American Journal of Hypertension},
year = {2025},
doi = {10.1093/ajh/hpaf029}
}
EUVIMED